MYGN Stock Analysis

Myriad Genetics Inc (MYGN): A Comprehensive StockValueFinder Review

Myriad Genetics Inc is a healthcare company operating in the diagnostics and research sector. This article provides an educational review of MYGN's performance using the metrics from StockValueFinder, focusing on financial health, valuation discipline, and market trends.

Why the StockValueFinder Score Matters The StockValueFinder score for Myriad Genetics Inc stands at 43%, with a rating of AVOID. The scoring system evaluates various financial metrics to determine if a stock is worth considering as an investment opportunity based on its current performance and risk profile. Given this score, investors should be cautious about MYGN due to the combination of low scores in several key areas.

EPS Strength and Consistency Earnings Per Share (EPS) measures profitability by dividing net income by outstanding shares. A consistent and growing EPS is a positive indicator for long-term investment potential. For Myriad Genetics Inc, the EPS test was not passed according to StockValueFinder's criteria. While detailed historical EPS figures are not provided, this result suggests that MYGN may be experiencing fluctuations or declines in earnings per share over time.

**Example**: A company with an EPS growth rate of 10% year-over-year is generally more attractive than one showing a decline or erratic performance. This consistency helps investors gauge the reliability and sustainability of earnings.

ROIC and Capital Efficiency Return on Invested Capital (ROIC) measures how effectively a company uses its capital to generate profits. StockValueFinder prefers companies with an ROIC of 10% or higher, indicating efficient use of resources. Myriad Genetics Inc has a negative ROIC of -63.33%, which is significantly below the preferred range.

**Example**: A company with a ROIC of 15% is using its capital more effectively than one with only 4%. Higher ROIC suggests better management and operational efficiency, leading to stronger financial performance over time.

Interest Coverage and Financial Safety Interest coverage ratio assesses a company's ability to pay interest on outstanding debt. StockValueFinder prefers companies with an interest coverage of at least 6 times earnings before interest and taxes (EBIT) compared to interest expense. Myriad Genetics Inc did not pass this test, indicating potential financial strain from high debt levels.

**Example**: A company with an interest coverage ratio of 8 is in a healthier position than one with only 2, as it can more easily cover its interest expenses without impacting operations or growth plans.

Debt Payback and Balance Sheet Discipline Debt payback period measures how long it would take for a company to repay all outstanding debt using current earnings before interest and taxes (EBIT). StockValueFinder prefers companies with a debt payback period of 3 years or less, indicating prudent financial management. Myriad Genetics Inc passed this test with a debt payback period of -4.68 years.

**Example**: A company that can repay its debts in 1.5 years is more financially disciplined than one requiring 7 years to do so, suggesting better risk management and operational stability.

P/E Ratio and Valuation Discipline Price-to-Earnings (P/E) ratio compares a stock's market price with its earnings per share, providing insight into valuation. StockValueFinder prefers companies with a P/E of 15 or lower for disciplined investment decisions. Myriad Genetics Inc has a negative P/E ratio of -25.30, which is not within the preferred range.

**Example**: A company with a P/E of 8 may be more undervalued than one with a P/E of 40, assuming similar business quality and growth prospects. However, a negative or extremely high P/E can indicate issues with earnings stability or market sentiment.

Moving Average Trend and Entry Timing Moving averages help identify trends in stock prices over time. StockValueFinder uses moving averages to determine entry timing rather than as proof of future price movements. For Myriad Genetics Inc, the moving average signal is NEUTRAL / WATCH, indicating no clear trend but a need for close monitoring.

**Example**: A positive moving average crossover might suggest an uptrend and potential buying opportunity, while a negative crossover could indicate selling pressure or a downtrend.

Overall Financial Strengths and Weaknesses Myriad Genetics Inc demonstrates strengths in debt payback period and P/E ratio valuation discipline. However, it falls short on EPS consistency, ROIC efficiency, interest coverage, and overall financial health as indicated by the low StockValueFinder score of 43%.

Risks and Limitations Investing in Myriad Genetics Inc involves risks related to earnings volatility, capital inefficiency, high debt levels, and potentially overvalued stock price based on current P/E ratios. These factors contribute to the AVOID rating from StockValueFinder.

Educational Conclusion This review of Myriad Genetics Inc using StockValueFinder metrics highlights the importance of evaluating multiple financial indicators before making investment decisions. Consistent earnings growth, efficient use of capital, strong interest coverage, and prudent debt management are crucial for long-term success. While valuation discipline is important, it must be balanced against other factors to form a comprehensive view of a company's health.

This article is for research and educational purposes only. It is not personal financial advice, investment advice, or a recommendation to buy or sell any security.

Research links: Yahoo Finance | Seeking Alpha | Finviz | SEC Filings